Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | GLS | O94925 | 3/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | KDR | P35968 | 4/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5914251 | 1.00 | BRD4 (0.38) | BRD4GLSAAK1CTSLMAPK14 | |
| SCHEMBL5914387 | 0.89 | BRD4 (0.35) | BRD4GLSCTSLMAPK14KDR | |
| SCHEMBL5264280 | 0.89 | MAPK14 (0.40) | MAPK14KDR | |
| SCHEMBL5914093 | 0.88 | MAPK14 (0.39) | BRD4GLSMAPK14KDRCYP3A4 | |
| SCHEMBL5914098 | 0.88 | MAPK14 (0.39) | BRD4GLSMAPK14KDRCYP3A4 | |
| SCHEMBL5914203 | 0.86 | GRM2 (0.41) | BRD4GLSMAPK14CYP3A4 | |
| SCHEMBL5914202 | 0.86 | GRM2 (0.41) | BRD4GLSMAPK14CYP3A4 | |
| SCHEMBL5914196 | 0.84 | KDR (0.38) | GLSAAK1MAPK14KDR | |
| SCHEMBL5914197 | 0.84 | KDR (0.38) | GLSAAK1MAPK14KDR | |
| SCHEMBL5914005 | 0.81 | NAMPT (0.37) | BRD4GLSMAPK14CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | BRD4 1477/4885GLS 819/4885AAK1 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.